HRP20191902T1 - Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe - Google Patents
Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20191902T1 HRP20191902T1 HRP20191902TT HRP20191902T HRP20191902T1 HR P20191902 T1 HRP20191902 T1 HR P20191902T1 HR P20191902T T HRP20191902T T HR P20191902TT HR P20191902 T HRP20191902 T HR P20191902T HR P20191902 T1 HRP20191902 T1 HR P20191902T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- vector
- acid sequence
- envelope protein
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims 15
- 239000013598 vector Substances 0.000 title claims 14
- 239000000203 mixture Substances 0.000 title claims 9
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 101710091045 Envelope protein Proteins 0.000 claims 10
- 101710188315 Protein X Proteins 0.000 claims 10
- 102100021696 Syncytin-1 Human genes 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 241000701161 unidentified adenovirus Species 0.000 claims 6
- 230000035772 mutation Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 230000000890 antigenic effect Effects 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000005829 trimerization reaction Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000598171 Human adenovirus sp. Species 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Claims (15)
1. Nukleinska kiselina koja kodira sintetski protein ovojnice HIV-a koji sadrži aminokiselinsku sekvencu SEQ ID NO: 8, ili SEQ ID NO:8 koja ima jednu ili više mutacija odabranih iz skupine koja se sastoji od (i) I529P, (ii) K480E, i (iii) kombinaciju EK479-480RRRR, I529P, A471C i T575C.
2. Nukleinska kiselina prema patentnom zahtjevu 1, naznačena time što sintetski protein ovojnice HIV-a nadalje sadrži signalnu sekvencu, na primjer, signalnu sekvencu koja sadrži aminokiselinsku sekvencu odabranu iz skupine koja sadrži SEQ ID NO:9 do SEQ ID NO: 12.
3. Nukleinska kiselina prema patentnom zahtjevu 1 ili 2, naznačena time što sintetski protein ovojnice HIV-a nadalje sadrži transmembransku domenu, na primjer, transmembransku domenu koja sadrži SEQ ID NO:13, poželjno sintetski protein ovojnice HIV-a nadalje sadrži SEQ ID NO:37 spojen na C-terminalni kraj SEQ ID NO:8 i N-terminalni kraj transmembranske domene.
4. Nukleinska kiselina prema patentnom zahtjevu 3, naznačena time što sintetski protein ovojnice HIV-a nadalje sadrži fragment citoplazmatske domene, poželjno fragment citoplazmatske domene sadrži aminokiselinsku sekvencu SEQ ID NO:14 ili njezine ostatke 1-4.
5. Nukleinska kiselina prema bilo kojem od prethodnih patentnih zahtjeva 1-4, naznačena time što sintetski protein ovojnice HIV-a sadrži aminokiselinsku sekvencu SEQ ID NO: 18.
6. Nukleinska kiselina prema patentnom zahtjevu 1 ili 2, naznačena time što sintetski protein ovojnice HIV-a ili: (a) nadalje sadrži trimerizacijsku domenu, na primjer trimerizacijsku domenu koja ima aminokiselinsku sekvencu SEQ ID NO: 15 ili SEQ ID NO:16; ili (b) sadrži SEQ ID NO:8 koja ima kombinaciju mutacija EK479-480RRRR, I529P, A471C i T575C.
7. Nukleinska kiselina prema patentnom zahtjevu 6, naznačena time što sintetski protein ovojnice za HIV sadrži aminokiselinsku sekvencu od ostataka 1-686 iz SEQ ID NO: 19.
8. Vektor koji sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što je nukleinska kiselina operativno povezana sa promotorskom sekvencom.
9. Vektor prema patentnom zahtjevu 8, naznačen time što virusni vektor, poželjno vektor adenovirusa.
10. Vektor prema patentnom zahtjevu 9, naznačen time što je vektor adenovirusa vektor ljudskog adenovirusa serotip 26 (Ad26).
11. Izolirana stanica naznačena time što sadrži vektor prema bilo kojem od patentnih zahtjeva 8-10.
12. Pripravak naznačen time što sadrži imunogeno učinkovitu količinu vektora prema bilo kojem od patentnih zahtjeva 8-10, i nosač.
13. Kombinacija cjepiva, koja sadrži:
(i) prvi pripravak koji sadrži imunogeno učinkovitu količinu vektora adenovirusa, poželjno vektor adenovirusa 26, koji kodira sintetski protein ovojnice HIV-a koji ima aminokiselinsku sekvencu SEQ ID NO: 8, poželjno SEQ ID NO: 18;
(ii) drugi pripravak koji sadrži imunogeno učinkovitu količinu drugog vektora adenovirusa, poželjno drugi vektor adenovirusa 26, koji kodira HIV antigeni polipeptid koji sadrži aminokiselinsku sekvencu SEQ ID NO: 5; te po izboru
(iii) najmanje jedan dodatni pripravak koji sadrži imunogeno učinkovitu količinu barem jednog odabranog iz skupine koja sadrži
(iiia) vektor koji kodira barem jedan antigeni polipeptid koji ima aminokiselinsku sekvencu odabranu iz skupine koja se sastoji od SEQ ID NOs: 1-4, 28 i 29, i
(iiib) polipeptid koji sadrži imunogeno učinkovitu količinu izoliranog HIV antigenog polipeptida koji ima ostatke 30-708 aminokiselinske sekvence SEQ ID NO: 7, ili ostatke 30-724 iz SEQ ID NO: 36,
pri čemu su prvi pripravak, drugi pripravak i dodatni pripravak prisutni u istom pripravku ili u jednom ili više različitih pripravaka.
14. Pripravak prema patentnom zahtjevu 12 ili kombinacija cjepiva prema patentnom zahtjevu 13 naznačena time što je za uporabu za induciranje imunološkog odgovora protiv virusa ljudske imunodeficijencije (HIV) kod subjekta kojem je to potrebno.
15. Sintetski protein ovojnice za HIV koji sadrži aminokiselinsku sekvencu SEQ ID NO:8 ili SEQ ID NO:8 s jednom ili više mutacija izabranih iz skupine koja se sastoji od (i) I529P, (ii) K480E, i (iii) kombinacije EK479-480RRRR, I529P, A471C i T575C, te poželjno, sadrži (i) SEQ ID NO:8 koja ima kombinaciju mutacija EK479-480RRRR, I529P, A471C i T575C; (ii) ostatke aminokiselina 30-704 od SEQ ID NO: 18, ili (iii) ostatke aminokiselina 30-686 od SEQ ID NO: 19.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15200138 | 2015-12-15 | ||
| EP16194124 | 2016-10-17 | ||
| EP16822410.3A EP3390430B1 (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
| PCT/EP2016/081159 WO2017102929A1 (en) | 2015-12-15 | 2016-12-15 | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191902T1 true HRP20191902T1 (hr) | 2020-01-24 |
Family
ID=57737697
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211566TT HRP20211566T1 (hr) | 2015-12-15 | 2016-12-15 | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe |
| HRP20191902TT HRP20191902T1 (hr) | 2015-12-15 | 2019-10-21 | Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211566TT HRP20211566T1 (hr) | 2015-12-15 | 2016-12-15 | Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10369214B2 (hr) |
| EP (3) | EP3964569A1 (hr) |
| JP (2) | JP6510149B2 (hr) |
| KR (1) | KR20180086207A (hr) |
| CN (2) | CN108368157B (hr) |
| AU (2) | AU2016369326B2 (hr) |
| BR (1) | BR112018011122A2 (hr) |
| CA (1) | CA3008542C (hr) |
| CY (2) | CY1122705T1 (hr) |
| DK (2) | DK3390430T3 (hr) |
| EA (1) | EA038974B1 (hr) |
| ES (2) | ES2898271T3 (hr) |
| HR (2) | HRP20211566T1 (hr) |
| HU (2) | HUE055916T2 (hr) |
| IL (1) | IL259942B2 (hr) |
| LT (2) | LT3584252T (hr) |
| MA (3) | MA47522B1 (hr) |
| MD (2) | MD3390430T2 (hr) |
| ME (1) | ME03545B (hr) |
| MX (2) | MX2018007198A (hr) |
| PH (1) | PH12018501047A1 (hr) |
| PL (2) | PL3584252T3 (hr) |
| PT (1) | PT3390430T (hr) |
| RS (2) | RS62360B1 (hr) |
| SG (2) | SG11201804411TA (hr) |
| SI (2) | SI3390430T1 (hr) |
| TW (2) | TWI792091B (hr) |
| WO (1) | WO2017102929A1 (hr) |
| ZA (1) | ZA201803978B (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
| MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
| JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
| CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
| MA49397A (fr) * | 2017-06-15 | 2020-04-22 | Bavarian Nordic As | Vecteurs à poxvirus codant pour des antigènes du vih, et leurs procédés d'utilisation |
| SG11202000112XA (en) * | 2017-07-19 | 2020-02-27 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| WO2019055888A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT |
| AR114560A1 (es) * | 2017-11-17 | 2020-09-23 | Grifols Diagnostic Solutions Inc | Proteínas antigénicas de la envoltura del virus de inmunodeficiencia humano expresadas en mamíferos |
| WO2020214203A1 (en) * | 2019-04-17 | 2020-10-22 | The Wistar Institute | Replication deficient adenoviral vectors for hiv vaccine applications |
| WO2020237052A1 (en) | 2019-05-22 | 2020-11-26 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| WO2021089770A2 (en) | 2019-11-07 | 2021-05-14 | Janssen Vaccines & Prevention B.V. | Protein purification |
| CA3182703A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| WO2022006095A2 (en) * | 2020-06-29 | 2022-01-06 | Duke University | Mosaic hiv-1 envelopes to induce adcc responses |
| WO2022084333A1 (en) | 2020-10-20 | 2022-04-28 | Janssen Vaccines & Prevention B.V. | Hiv vaccine regimens |
| CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| WO2023242155A1 (en) | 2022-06-14 | 2023-12-21 | Janssen Vaccines & Prevention B.V. | Compositions and methods for the diagnosis of hiv infection |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US5761893A (en) | 1996-10-22 | 1998-06-09 | Lofquist Welding, Inc. | Crop saving attachment for the snouts of combines |
| DE60043126D1 (de) | 1999-05-17 | 2009-11-19 | Crucell Holland Bv | Von Adenovirus abgeleitete Gentransfervehikel, die zumindest ein Element des Adenovirus Typ 35 enthalten |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US6710173B1 (en) | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| CA2384271A1 (en) * | 1999-09-17 | 2001-03-22 | Joseph G. Sodroski | Stabilized soluble glycoprotein trimers |
| EP1598425A1 (en) | 2000-11-23 | 2005-11-23 | Bavarian Nordic A/S | Modified Vaccinia Ankara virus variant |
| EP2280074A3 (en) * | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| CA2785699A1 (en) * | 2001-07-05 | 2003-01-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| CN101397574A (zh) | 2001-12-04 | 2009-04-01 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| PL215165B1 (pl) | 2002-04-25 | 2013-10-31 | Crucell Holland Bv | Rekombinowany wektor adenowirusowy oraz sposób wytwarzania rekombinowanego wektora adenowirusowego |
| US7285265B2 (en) | 2002-04-25 | 2007-10-23 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| AU2003291402A1 (en) | 2002-11-07 | 2004-06-03 | Beth Israel Deaconess Medical Center | MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE |
| US7901690B2 (en) | 2002-12-03 | 2011-03-08 | University Of Massachusetts | Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods |
| EP2363143A3 (en) | 2003-03-28 | 2012-02-15 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | MVA expressing modified hiv envelope, gag, and pol genes |
| US20070166784A1 (en) | 2003-09-15 | 2007-07-19 | Barnett Susan W | Combination approaches for generating immune responses |
| US20070298051A1 (en) | 2003-11-19 | 2007-12-27 | Beth Israel Deaconess Medical Center | Adjuvants Of Immune Response |
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| EP2567967A3 (en) * | 2004-04-12 | 2013-08-21 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method of using adenoviral vectors to induce an immune response |
| EP1766097A4 (en) | 2004-06-15 | 2008-03-19 | Progenics Pharm Inc | HIV-1 NEUTRALIZATION ANTIBODIES ELICITED BY A TRIMERIC COMPLEX OF HIV-1 ENVELOPE GLYCOPROTEINS |
| AU2005274948B2 (en) * | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| US9453239B2 (en) * | 2004-08-27 | 2016-09-27 | Emory University | Recombinant MVA viruses expressing clade A/G, clade B, and clade C modified HIV env, gag and pol genes |
| AP2351A (en) | 2004-10-13 | 2012-01-25 | Crucell Holland Bv | Improved adenoviral vectors and uses thereof. |
| CN101588813A (zh) * | 2005-04-12 | 2009-11-25 | 杜克大学 | 诱导人类免疫缺陷病毒的中和抗体的方法 |
| CA2656741A1 (en) | 2005-07-06 | 2007-01-11 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
| AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| CA2655934A1 (en) | 2006-06-19 | 2007-12-27 | Progenics Pharmaceuticals, Inc. | Soluble stabilized trimeric hiv env proteins and uses thereof |
| WO2008063331A2 (en) | 2006-10-23 | 2008-05-29 | Progenics Pharmaceuticals, Inc. | Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof |
| WO2008140579A2 (en) | 2006-11-17 | 2008-11-20 | New York University | Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| AU2008223951B2 (en) | 2007-03-02 | 2014-03-27 | Glaxosmithkline Biologicals S.A. | Novel method and compositions |
| PT3335728T (pt) | 2008-10-10 | 2020-02-19 | Childrens Medical Center | Vacina de trímero de envelope para hiv-1 bioquimicamente estabilizada |
| DK2358757T3 (da) * | 2008-11-18 | 2019-01-02 | Beth Israel Deaconess Medical Ct Inc | Antivirale vacciner med forbedret cellulær immunogenicitet |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| WO2011082087A2 (en) | 2010-01-04 | 2011-07-07 | Kj Biosciences, Llc | Dps fusion proteins for use in vaccines and diagnostics |
| CA2786333C (en) | 2010-01-28 | 2018-03-20 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
| EP2926830B1 (en) | 2010-08-31 | 2017-08-02 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
| AU2011343798B2 (en) | 2010-12-14 | 2016-07-14 | Janssen Vaccines & Prevention B.V. | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
| AP2013007180A0 (en) * | 2011-04-25 | 2013-10-31 | Advanced Bioscience Lab Inc | Truncated HIV envelope proteins (ENV), methods andcompositions related thereto |
| US20140348791A1 (en) | 2011-09-09 | 2014-11-27 | Beth Israel Deaconess Medical Center, Inc. | Modified adenoviral vectors and methods of treatment using same |
| US20130189754A1 (en) | 2011-09-12 | 2013-07-25 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies |
| WO2013040766A1 (zh) * | 2011-09-21 | 2013-03-28 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 可诱导针对hiv的广谱免疫应答的方法和疫苗 |
| WO2013055908A1 (en) | 2011-10-12 | 2013-04-18 | The Scripps Research Institute | An hiv-1 gp120 mini v3 loop and uses thereof |
| WO2014047261A1 (en) | 2012-09-19 | 2014-03-27 | Beth Israel Deaconess Medical Center, Inc. | Viruses associated with immunodeficiency and enteropathy and methods using same |
| CN105051198A (zh) | 2012-11-16 | 2015-11-11 | 貝丝以色列女执事医疗中心 | 重组腺病毒及其用途 |
| SG11201505229XA (en) | 2013-01-07 | 2015-08-28 | Beth Israel Hospital | Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same |
| WO2014124301A1 (en) | 2013-02-07 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Self-assembling protein nanostructures |
| US9624510B2 (en) * | 2013-03-01 | 2017-04-18 | The Wistar Institute | Adenoviral vectors comprising partial deletions of E3 |
| US10376583B2 (en) | 2013-09-30 | 2019-08-13 | Beth Israel Deaconess Medical Center, Inc. | Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator |
| US10716845B2 (en) * | 2013-10-04 | 2020-07-21 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same |
| CA2941116A1 (en) * | 2014-02-28 | 2015-09-03 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| EP3189067B1 (en) | 2014-09-04 | 2021-05-19 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant hiv-1 envelope proteins and their use |
| ES2865150T3 (es) | 2014-09-26 | 2021-10-15 | Beth Israel Deaconess Medical Ct Inc | Métodos y composiciones para inducir inmunidad protectora contra la infección por el virus de la inmunodeficiencia humana |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| LT3271729T (lt) * | 2015-03-18 | 2021-02-25 | Janssen Vaccines & Prevention B.V. | Rekombinantinių raiškos sistemų analizės būdai |
| JP6510149B2 (ja) | 2015-12-15 | 2019-05-08 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | ヒト免疫不全ウイルス抗原、ベクター、組成物、およびその使用方法 |
| KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
| CA3035759A1 (en) | 2016-09-02 | 2018-03-08 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| BR112019004593A2 (pt) | 2016-09-15 | 2019-07-02 | Janssen Vaccines & Prevention Bv | mutações da proteína do envelope do hiv estabilizando o trímero |
| DE102018124348A1 (de) | 2018-10-02 | 2020-04-02 | Haver & Boecker Ohg | Füllkasten und Verfahren zum Füllen von Gebinden |
-
2016
- 2016-12-15 JP JP2018531537A patent/JP6510149B2/ja active Active
- 2016-12-15 EA EA201891415A patent/EA038974B1/ru unknown
- 2016-12-15 HR HRP20211566TT patent/HRP20211566T1/hr unknown
- 2016-12-15 ES ES19186284T patent/ES2898271T3/es active Active
- 2016-12-15 AU AU2016369326A patent/AU2016369326B2/en active Active
- 2016-12-15 CA CA3008542A patent/CA3008542C/en active Active
- 2016-12-15 HU HUE19186284A patent/HUE055916T2/hu unknown
- 2016-12-15 MA MA47522A patent/MA47522B1/fr unknown
- 2016-12-15 SG SG11201804411TA patent/SG11201804411TA/en unknown
- 2016-12-15 ES ES16822410T patent/ES2753854T3/es active Active
- 2016-12-15 HU HUE16822410A patent/HUE045993T2/hu unknown
- 2016-12-15 TW TW109138473A patent/TWI792091B/zh active
- 2016-12-15 ME MEP-2019-304A patent/ME03545B/me unknown
- 2016-12-15 EP EP21185351.0A patent/EP3964569A1/en not_active Withdrawn
- 2016-12-15 TW TW105141650A patent/TWI707039B/zh active
- 2016-12-15 CN CN201680073839.5A patent/CN108368157B/zh active Active
- 2016-12-15 MX MX2018007198A patent/MX2018007198A/es unknown
- 2016-12-15 CN CN202210312432.0A patent/CN114686495A/zh active Pending
- 2016-12-15 PL PL19186284T patent/PL3584252T3/pl unknown
- 2016-12-15 IL IL259942A patent/IL259942B2/en unknown
- 2016-12-15 SI SI201630480T patent/SI3390430T1/sl unknown
- 2016-12-15 US US15/380,123 patent/US10369214B2/en active Active
- 2016-12-15 DK DK16822410T patent/DK3390430T3/da active
- 2016-12-15 WO PCT/EP2016/081159 patent/WO2017102929A1/en active Application Filing
- 2016-12-15 MA MA055825A patent/MA55825A/fr unknown
- 2016-12-15 PL PL16822410T patent/PL3390430T3/pl unknown
- 2016-12-15 RS RS20211171A patent/RS62360B1/sr unknown
- 2016-12-15 EP EP16822410.3A patent/EP3390430B1/en active Active
- 2016-12-15 MA MA44059A patent/MA44059B1/fr unknown
- 2016-12-15 LT LTEP19186284.6T patent/LT3584252T/lt unknown
- 2016-12-15 RS RSP20191399 patent/RS59447B1/sr unknown
- 2016-12-15 KR KR1020187016460A patent/KR20180086207A/ko not_active Application Discontinuation
- 2016-12-15 EP EP19186284.6A patent/EP3584252B1/en active Active
- 2016-12-15 PT PT168224103T patent/PT3390430T/pt unknown
- 2016-12-15 BR BR112018011122-8A patent/BR112018011122A2/pt active Search and Examination
- 2016-12-15 SG SG10202109457R patent/SG10202109457RA/en unknown
- 2016-12-15 LT LT16822410T patent/LT3390430T/lt unknown
- 2016-12-15 SI SI201631333T patent/SI3584252T1/sl unknown
- 2016-12-15 MD MDE20181009T patent/MD3390430T2/ro unknown
- 2016-12-15 DK DK19186284.6T patent/DK3584252T3/da active
- 2016-12-15 MD MDE20200025T patent/MD3584252T2/ro unknown
-
2018
- 2018-05-16 PH PH12018501047A patent/PH12018501047A1/en unknown
- 2018-06-13 MX MX2021006931A patent/MX2021006931A/es unknown
- 2018-06-14 ZA ZA2018/03978A patent/ZA201803978B/en unknown
-
2019
- 2019-04-03 JP JP2019071336A patent/JP6959289B2/ja active Active
- 2019-05-17 AU AU2019203468A patent/AU2019203468B2/en not_active Ceased
- 2019-06-13 US US16/440,463 patent/US10973907B2/en active Active
- 2019-10-21 HR HRP20191902TT patent/HRP20191902T1/hr unknown
- 2019-11-13 CY CY20191101197T patent/CY1122705T1/el unknown
-
2021
- 2021-03-03 US US17/190,569 patent/US11896663B2/en active Active
- 2021-10-19 CY CY20211100901T patent/CY1125387T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191902T1 (hr) | Antigeni virusa ljudske imunodeficijencije, vektori, pripravci, i postupci njihove upotrebe | |
| HRP20200871T1 (hr) | Izmjenjeni rsv f proteini i postupci njihove uporabe | |
| HRP20190907T1 (hr) | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) | |
| CY1124202T1 (el) | Εμβολια ανασυνδυασμενου zika | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| JP2018528253A5 (hr) | ||
| HRP20150479T1 (hr) | Multimeriäśna multiepitopska cjepiva protiv influence | |
| JP2015524422A5 (hr) | ||
| HRP20171703T1 (hr) | Predfuzijski antigeni rsv f | |
| JP2015212284A5 (hr) | ||
| JP2016510983A5 (hr) | ||
| JP2015096070A5 (hr) | ||
| EA201990718A1 (ru) | Векторы аденовируса собачьих | |
| RU2015135890A (ru) | Композиция вакцины | |
| JP2018531624A5 (hr) | ||
| WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
| HRP20181055T1 (hr) | Antagonisti kv1.3 i postupci upotrebe | |
| HK1127731A1 (en) | Chimeric viruses presenting non-native surface proteins and uses thereof | |
| HRP20200285T1 (hr) | Postupci i pripravci za induciranje zaštitnog imuniteta protiv zaraze filovirusom | |
| WO2014150822A3 (en) | Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use | |
| JP2015524403A5 (hr) | ||
| HRP20220980T1 (hr) | Cjepiva protiv virusa influence i njihova uporaba | |
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| EA201890110A1 (ru) | Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения | |
| WO2015107363A3 (en) | Mycobacterial antigen composition |